R. Nick Bryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
R. Nick Bryan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Anne Murray
Hennepin County Medical Center, Minneapolis, MN
2 shared publications- Christos Davatzikos
Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI2D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
2 shared publications James Lovato
Wake Forest University, Winston Salem, NC
2 shared publicationsJeff Williamson
Wake Forest University, Winston Salem, NC
2 shared publicationsLenore J. Launer
National Institute on Aging, Bethesda, MD
2 shared publicationsMichael E. Miller
Wake Forest University, Winston Salem, NC
2 shared publications
Latest Publications
- 1 October 2018
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 32 (10) , 916-921
Relationships between cerebral structure and cognitive function in African Americans with type 2 diabetes
- 1 October 2018
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 32 (10) , 916-921
Relationships between cerebral structure and cognitive function in African Americans with type 2 diabetes
- 1 December 2016
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 281 (3) , 665-668
Machine Learning Applied to Alzheimer Disease
The diagnostic test described by Collij et al has three important features, each of which could influence its clinical potential: (a) measurement of cerebral blood flow, a physiological parameter relevant to Alzheimer disease; (b) arterial spin labeling MR imaging, a relatively novel, noninvasive signal intensity detection scheme; and (c) a contemporary machine learning approach to image analysis.
- 1 December 2016
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 281 (3) , 665-668
Machine Learning Applied to Alzheimer Disease
The diagnostic test described by Collij et al has three important features, each of which could influence its clinical potential: (a) measurement of cerebral blood flow, a physiological parameter relevant to Alzheimer disease; (b) arterial spin labeling MR imaging, a relatively novel, noninvasive signal intensity detection scheme; and (c) a contemporary machine learning approach to image analysis.
- 1 October 2016
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 281 (1) , 1-3
Science to Practice: Can Focused Ultrasound Disruption of the Blood-Brain Barrier Improve Malignant Brain Tumor Treatment Outcomes?
A relatively novel combination treatment for malignant brain tumors that includes focused ultrasound has been shown to improve tumor response and treatment outcome in a preclinical mouse model. SummaryA relatively novel combination treatment for malignant brain tumors that includes focused ultrasound has been shown to improve tumor response and treatment outcome in a preclinical mouse model. This method directly addresses the great need for better treatments for this lethal disease. However, there are substantial technologic hurdles that must be addressed before clinical efficacy will be known. Unfortunately, few of these questions can be readily answered outside the clinical environment. Although it would be enormously challenging, a phase I clinical trial seems feasible and needed to determine the clinical value of this technique.
- 1 October 2016
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 281 (1) , 1-3
Science to Practice: Can Focused Ultrasound Disruption of the Blood-Brain Barrier Improve Malignant Brain Tumor Treatment Outcomes?
A relatively novel combination treatment for malignant brain tumors that includes focused ultrasound has been shown to improve tumor response and treatment outcome in a preclinical mouse model. SummaryA relatively novel combination treatment for malignant brain tumors that includes focused ultrasound has been shown to improve tumor response and treatment outcome in a preclinical mouse model. This method directly addresses the great need for better treatments for this lethal disease. However, there are substantial technologic hurdles that must be addressed before clinical efficacy will be known. Unfortunately, few of these questions can be readily answered outside the clinical environment. Although it would be enormously challenging, a phase I clinical trial seems feasible and needed to determine the clinical value of this technique.
- Open Access
- 8 November 2014
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (12) , 3279-3285
Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial
OBJECTIVE: The effect of hypoglycemia related to treatment of type 2 diabetes mellitus (T2DM) on brain structure remains unclear. We aimed to assess whether symptomatic severe hypoglycemia is associated with brain atrophy and/or white matter abnormalities. RESEARCH DESIGN AND METHODS: We included T2DM participants with brain MRI from the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Symptomatic severe hypoglycemia was defined as blood glucose <2.8 mmol/L or symptoms resolved with treatments that required the assistance of another person or medical assistance (hypoglycemia requiring assistance [HA]). Standardized brain MRI was performed at baseline and at 40 months. Total brain volume (TBV) and abnormal white matter (AWM) volume were calculated using an automated computer algorithm. Brain MRI scans of hypoglycemic participants were also reviewed for local disease. RESULTS: Of the 503 T2DM participants (mean age, 62 years) with successful baseline and 40-month brain MRI, 28 had at least one HA episode during the 40-month follow-up. Compared with participants without HA, those with HA had marginally significant less atrophy (less decrease in TBV) from baseline to 40 months (−9.55 [95% CI −15.21, −3.90] vs. −15.38 [95% CI −16.64, −14.12], P = 0.051), and no significant increase of AWM volume (2.06 [95% CI 1.71, 2.49] vs. 1.84 [95% CI 1.76, 1.91], P = 0.247). In addition, no unexpected local signal changes or volume loss were seen on hypoglycemic participants’ brain MRI scans. CONCLUSIONS: Our study suggests that hypoglycemia related to T2DM treatment may not accentuate brain pathology, specifically brain atrophy or white matter abnormalities.
- 8 November 2014
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (12) , 3279-3285
Open AccessEffect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial
OBJECTIVE: The effect of hypoglycemia related to treatment of type 2 diabetes mellitus (T2DM) on brain structure remains unclear. We aimed to assess whether symptomatic severe hypoglycemia is associated with brain atrophy and/or white matter abnormalities. RESEARCH DESIGN AND METHODS: We included T2DM participants with brain MRI from the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Symptomatic severe hypoglycemia was defined as blood glucose <2.8 mmol/L or symptoms resolved with treatments that required the assistance of another person or medical assistance (hypoglycemia requiring assistance [HA]). Standardized brain MRI was performed at baseline and at 40 months. Total brain volume (TBV) and abnormal white matter (AWM) volume were calculated using an automated computer algorithm. Brain MRI scans of hypoglycemic participants were also reviewed for local disease. RESULTS: Of the 503 T2DM participants (mean age, 62 years) with successful baseline and 40-month brain MRI, 28 had at least one HA episode during the 40-month follow-up. Compared with participants without HA, those with HA had marginally significant less atrophy (less decrease in TBV) from baseline to 40 months (−9.55 [95% CI −15.21, −3.90] vs. −15.38 [95% CI −16.64, −14.12], P = 0.051), and no significant increase of AWM volume (2.06 [95% CI 1.71, 2.49] vs. 1.84 [95% CI 1.76, 1.91], P = 0.247). In addition, no unexpected local signal changes or volume loss were seen on hypoglycemic participants’ brain MRI scans. CONCLUSIONS: Our study suggests that hypoglycemia related to T2DM treatment may not accentuate brain pathology, specifically brain atrophy or white matter abnormalities.
- 1 July 2014
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 272 (1) , 210-216
Effect of Diabetes on Brain Structure: The Action to Control Cardiovascular Risk in Diabetes MR Imaging Baseline Data
The results of this study show that measures of longer duration of diabetes or biochemical severity correlated primarily with brain atrophy, but not with white matter lesion volume, which is the ma... PurposeTo investigate the association of characteristics of type 2 diabetes mellitus (duration and biochemical severity of diabetes) to brain structure measured on magnetic resonance (MR) images, s...
- 1 July 2014
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 272 (1) , 210-216
Effect of Diabetes on Brain Structure: The Action to Control Cardiovascular Risk in Diabetes MR Imaging Baseline Data
The results of this study show that measures of longer duration of diabetes or biochemical severity correlated primarily with brain atrophy, but not with white matter lesion volume, which is the ma... PurposeTo investigate the association of characteristics of type 2 diabetes mellitus (duration and biochemical severity of diabetes) to brain structure measured on magnetic resonance (MR) images, s...
- 1 February 2012
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 262 (2) , 375-377
Science to Practice: Is T2* Enough to Assess Oxygenation?
As initially reported by Ogawa et al (1), the magnetic resonance (MR) imaging T2* blood oxygen level–dependent (BOLD) signal is sensitive to blood oxygen concentration; however, this signal is also sensitive to a number of other normal and abnormal tissue features. As a result, T2* imaging alone cannot be used to accurately measure vascular oxygenation, much less tissue oxygenation. However, with separate MR imaging measurements of other tissue factors influencing T2*, it might be possible to noninvasively image local tissue oxygen. Such a capability could be of great clinical importance, not only in patients with hypoxic or ischemic disease states, but also in patients with other pathologic conditions that have abnormal respiratory metabolism, such as cancer.
- 1 February 2012
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 262 (2) , 375-377
Science to Practice: Is T2* Enough to Assess Oxygenation?
As initially reported by Ogawa et al (1), the magnetic resonance (MR) imaging T2* blood oxygen level–dependent (BOLD) signal is sensitive to blood oxygen concentration; however, this signal is also sensitive to a number of other normal and abnormal tissue features. As a result, T2* imaging alone cannot be used to accurately measure vascular oxygenation, much less tissue oxygenation. However, with separate MR imaging measurements of other tissue factors influencing T2*, it might be possible to noninvasively image local tissue oxygen. Such a capability could be of great clinical importance, not only in patients with hypoxic or ischemic disease states, but also in patients with other pathologic conditions that have abnormal respiratory metabolism, such as cancer.
- 30 November 2007
- Published by Elsevier in Neuroimaging Clinics Of North America
- Vol. 17 (4) , 397-405
Imaging of the Mind: Yesterday's Triumphs and Tomorrow's Challenges
- 30 November 2007
- Published by Elsevier in Neuroimaging Clinics Of North America
- Vol. 17 (4) , 397-405
Imaging of the Mind: Yesterday's Triumphs and Tomorrow's Challenges